A clinical trial is a research study that involves human participants to evaluate the safety, efficacy, and/or effectiveness of a medical intervention, such as a drug, treatment, device, or procedure. The primary purpose of clinical trials is to generate scientific data that can inform medical decision-making and contribute to advancements in healthcare. These studies follow a structured protocol or plan that outlines the objectives, design, methodology, and criteria for participant eligibility.

There are several types of clinical trials, each serving different purposes. The main types include:

1. Treatment Trials:
   • Drug Trials: Investigate new medications or combinations of medications.
   • Device Trials: Assess the safety and effectiveness of new medical devices.
   • Biological Product Trials: Study vaccines, gene therapies, or other biological products.
2. Prevention Trials:
   • Examine ways to prevent diseases or conditions. This can include trials for vaccines, medications, or lifestyle interventions.
3. Diagnostic Trials:
   • Develop and assess new diagnostic tools or procedures to detect diseases or conditions.
4. Screening Trials:
   • Evaluate methods to identify individuals at risk for a particular disease or condition.
5. Behavioral Trials:
   • Investigate behavioral interventions, lifestyle changes, or psychological approaches and their impact on health outcomes.
6. Observational Trials:
   • Observe and collect data on participants’ health without intervening or providing a specific treatment.
7. Phases of Clinical Trials:
   • Phase 0: Exploratory studies to gather initial data on how a drug behaves in the human body. This phase involves 10 – 15 participants and is not always a formal part of the drug development process.
   • Phase I: Initial testing in a small group of 20 – 100 healthy volunteers to determine the safety profile, dosage range, and potential side effects of the investigational drug.
   • Phase II: Expanded testing in 100’s of participants, including individuals with the target condition. The focus is on assessing the drug’s effectiveness and further evaluating its safety.
   • Phase III: Large-scale trials involving a diverse group of 100’s-1000’s participants to confirm the drug’s effectiveness, monitor side effects, and compare it to standard treatments or a placebo. These trials provide the most robust evidence for regulatory approval.
   • Phase IV: Post-marketing surveillance studies conducted after regulatory approval to monitor the intervention’s long-term safety and effectiveness in a larger population.
8. Randomized Controlled Trials (RCTs):
   • Many clinical trials, especially in Phase III, are randomized controlled trials. Participants are randomly assigned to different groups (e.g., treatment group and control group), which helps ensure unbiased results.
9. Blind and Double-Blind Trials:
   • Trials may be single-blind (participants are unaware of their assigned treatment) or double-blind (both participants and investigators are unaware). Blinding helps minimize biases in the study.
10. Cross-Over Trials:
    • Participants may receive different interventions at different times to compare their effects.

Clinical trials are conducted with strict ethical standards to ensure participant safety and the scientific integrity of the research process. They play a crucial role in advancing medical knowledge and improving patient care.

Before clinical trials commence, a rigorous and systematic process unfolds to evaluate the safety, efficacy, and feasibility of a potential medical intervention. This journey typically initiates with the discovery and preclinical research phase, where scientists delve into understanding the biological mechanisms, disease pathways, and potential therapeutic targets. In this phase, in vitro studies, conducted in a controlled laboratory environment, and in vivo studies involving animal models are crucial for assessing the intervention’s basic characteristics, safety profile, and potential side effects.

Once promising results emerge from preclinical research, investigators compile their findings into an Investigational New Drug (IND) application. This comprehensive submission includes data from preclinical studies, details about manufacturing processes, and proposed plans for upcoming clinical trials. The regulatory authorities, such as the U.S. Food and Drug Administration (FDA), rigorously review the IND application to ensure ethical standards, safety, and adherence to regulatory guidelines.

Upon successful review, the intervention progresses to Phase 0 and Phase 1 clinical trials. Phase 0 trials are exploratory, involving a small number of participants to understand the intervention’s behavior within the body. Phase 1 trials expand the study group to include healthy volunteers and focus on establishing the intervention’s safety, optimal dosage range, and potential side effects.

Positive outcomes from Phase 1 trials pave the way for Phase 2 clinical trials, which involve a larger group of participants, often those afflicted by the target condition. The primary objectives of Phase 2 trials include gathering preliminary data on efficacy, further assessing safety, and determining the intervention’s potential benefits.

If Phase 2 trials prove successful, the intervention advances to Phase 3, a pivotal stage where a more extensive and diverse population is involved. Phase 3 trials are designed to provide robust evidence regarding the intervention’s efficacy, monitor side effects comprehensively, and often compare the new intervention with existing treatments or a placebo.

Following successful completion of Phase 3, investigators compile a New Drug Application (NDA) containing a wealth of data, including detailed information on safety, efficacy, manufacturing processes, and proposed labeling. Regulatory agencies conduct an exhaustive review of the NDA, and if satisfied, grant approval for the intervention’s marketing and use in the broader population.

The post-marketing phase, known as Phase 4, involves ongoing surveillance to monitor the intervention’s real-world safety and effectiveness in larger populations over an extended period. This comprehensive and meticulous journey, from discovery to regulatory approval, ensures that only interventions with proven safety and efficacy profiles reach the market for the benefit of patients and public health.

The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has developed guidelines for Good Clinical Practice (GCP) to ensure the ethical and scientific integrity of clinical trials. Here’s a detailed explanation of clinical trial terminology according to ICH/GCP:

1. Clinical Trial:
   • A systematic study designed to evaluate and assess the safety, efficacy, and/or performance of a medical product (intervention) in human subjects.
2. Protocol:
   • The written plan detailing the objectives, design, methodology, statistical considerations, and organization of a clinical trial. The protocol serves as the master document guiding the conduct of the study.
3. Informed Consent:
   • The voluntary agreement by a participant, after being provided with comprehensive information about the clinical trial, including its purpose, procedures, potential risks, and benefits. Informed consent is obtained before any study-related activities are initiated.
4. Randomized Controlled Trial (RCT):
   • A study design where participants are randomly assigned to different treatment groups, allowing for the comparison of outcomes between groups and minimizing bias.
5. Placebo:
   • An inactive substance or treatment with no therapeutic effect, used in controlled trials to assess the specific effects of the active intervention.
6. Blinding (Masking):
   • The practice of keeping certain information, such as treatment assignments, undisclosed to participants, investigators, or both, to minimize bias in the study results. Double-blind studies involve both participants and investigators being unaware of treatment assignments.
7. Phase 0, 1, 2, 3, 4 Trials:
   • Clinical trials are categorized into phases based on their objectives and the number of participants. Each phase serves a specific purpose, from initial safety assessments (Phase 0) to post-marketing surveillance (Phase 4).
8. Endpoint:
   • A specific measure used to determine the efficacy or safety of a treatment in a clinical trial. Primary endpoints are the main outcomes of interest.
9. Adverse Event (AE) and Adverse Drug Reaction (ADR):
   • An Adverse Event is any untoward medical occurrence in a participant during a clinical trial. An Adverse Drug Reaction specifically refers to a harmful and unintended response resulting from the use of a drug.
10. Comparator:
    • The standard or reference treatment used for comparison with the experimental intervention in a clinical trial. It could be an existing treatment, placebo, or another control group.
11. Monitoring and Data Safety Monitoring Board (DSMB):
    • Continuous and independent review of a clinical trial’s progress, safety data, and adherence to the protocol. The DSMB may recommend modifications or early termination based on their findings.
12. Investigator:
    • The individual responsible for the conduct of the clinical trial at a trial site. This includes ensuring compliance with the protocol, safeguarding participant rights, and maintaining accurate and complete documentation.
13. Inclusion and Exclusion Criteria:
    • Specific characteristics or conditions that define who can (inclusion criteria) or cannot (exclusion criteria) participate in a clinical trial. These criteria ensure a homogeneous study population and ethical research practices.
14. Good Clinical Practice (GCP):
    • A set of international ethical and scientific standards for designing, conducting, recording, and reporting clinical trials. Adherence to GCP is essential for ensuring the reliability and integrity of trial data.
15. Serious Adverse Event (SAE):
    • Any adverse event that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, or is a congenital anomaly or birth defect.
16. Clinical Study Report (CSR):
    • A comprehensive document that summarizes the design, conduct, results, and conclusions of a clinical trial. It is a key document submitted to regulatory authorities for marketing authorization.
17. Quality Assurance (QA) and Quality Control (QC):
    • QA involves systematic activities to ensure that the trial is conducted, and data are generated, documented, and reported in compliance with GCP. QC involves operational techniques and activities to fulfill quality requirements.
18. Monitoring Visit:
    • A visit to the clinical trial site by a monitor (a representative of the sponsor) to verify the conduct of the trial, compliance with the protocol, and the accuracy of data collected.
19. Site Initiation Visit (SIV) and Close-Out Visit (COV):
    • SIV occurs before a site starts enrolling participants and involves training site staff on protocol requirements. COV occurs after the trial’s completion and involves the sponsor reviewing the site’s conduct and documentation.
20. Audit:
    • A systematic and independent examination of trial-related activities and documents to determine whether the evaluated trial-related activities were conducted and the data were recorded, analyzed, and accurately reported according to the protocol, sponsor’s standard operating procedures, GCP, and applicable regulatory requirements.

Understanding these terms in the context of ICH/GCP is crucial for all stakeholders involved in clinical trials to ensure the ethical conduct and validity of research findings.

For more information please visit the website of CDISC Terminology. 

Clinical trials are research studies that involve human participants to evaluate the safety and efficacy of new medical treatments, interventions, or devices. Regulations, ethics, and safety approaches play crucial roles in ensuring the integrity of clinical trials and the well-being of participants. Here’s a detailed overview of these aspects:

1. Regulations:

a. International Conference on Harmonisation (ICH):

• Purpose: To develop guidelines for the global pharmaceutical industry to ensure the safety, efficacy, and quality of drugs.
• Key Guidelines:
  • ICH-GCP (Good Clinical Practice): Ensures the ethical and scientific quality of clinical trials.
  • ICH-E6: Focuses on the management and conduct of clinical trials.

b. Declaration of Helsinki:

• Purpose: Provides ethical principles for medical research involving human subjects, emphasizing participant welfare and rights.
• Key Principles:
  • Informed consent
  • Scientific and social value of the research
  • Independent review by an ethics committee

c. FDA Regulations (U.S.):

• Purpose: Ensures the safety and effectiveness of drugs and medical devices.
• Key Regulations:
  • Investigational New Drug (IND) application
  • New Drug Application (NDA)
  • Institutional Review Board (IRB) oversight

d. European Medicines Agency (EMA) Regulations:

• Purpose: Regulates medicines for use in the European Union.
• Key Regulations:
  • Clinical Trial Regulation (CTR)
  • Good Clinical Practice (GCP)

e. Turkish Regulatory Authorities:

• Purpose: Each country may have its regulatory framework for clinical trials.
• Key Requirements:
  • Compliance with national laws and guidelines.

2. Ethics:

a. Informed Consent:

• Importance: Ensures participants are fully informed about the trial before agreeing to participate.
• Components:
  • Purpose and procedures
  • Risks and benefits
  • Confidentiality and voluntariness

b. Institutional Review Board (IRB):

• Role: Independent body that reviews, approves, and monitors the conduct of clinical trials.
• Responsibilities:
  • Protecting participant rights
  • Assessing scientific merit
  • Ensuring trial conduct follows ethical principles

c. Patient Privacy and Confidentiality:

• Importance: Safeguarding participant data and maintaining confidentiality.
• Measures:
  • Use of anonymized data
  • Secure data storage and transmission

3. Safety Approaches:

a. Adverse Event Reporting:

• Definition: Any untoward medical occurrence in a participant during a clinical trial.
• Reporting Requirements:
  • Timely reporting to regulatory authorities and ethics committees.

b. Data Monitoring Committees (DMC):

• Role: Independent committee that monitors participant safety and data integrity.
• Responsibilities:
  • Recommending trial continuation, modification, or termination.

c. Safety Pharmacovigilance:

• Purpose: Identifying, evaluating, and preventing adverse effects of drugs.
• Components:
  • Ongoing safety monitoring during and after trials.

d. Quality Assurance and Control:

• Purpose: Ensuring the quality and reliability of trial data.
• Measures:
  • Regular audits and inspections
  • Adherence to GCP standards

Conclusion: Effective clinical trial management requires a comprehensive understanding and adherence to regulatory guidelines, ethical principles, and safety approaches. The collaboration between investigators, regulatory authorities, ethics committees, and participants is essential to uphold the highest standards of integrity and safety in clinical research.

Here’s a detailed breakdown of the key stakeholders involved in clinical trials:

1. Investigators:
   • Role: Scientists, doctors, or healthcare professionals leading and conducting the clinical trial.
   • Responsibilities: Design the study, develop the protocol, recruit and enroll participants, oversee the trial’s progress, collect and analyze data, and publish results.
2. Participants/Patients:
   • Role: Individuals who volunteer to participate in the clinical trial.
   • Responsibilities: Follow the trial protocol, receive the assigned treatment (either the experimental or standard treatment), undergo various assessments, and provide informed consent.
3. Sponsors:
   • Role: Organizations or individuals providing funding, resources, and support for the clinical trial.
   • Responsibilities: Financially support the trial, contribute to study design, ensure compliance with regulations, and may be involved in data analysis.
4. Ethics Committees/Institutional Review Boards (IRBs):
   • Role: Independent groups of experts ensuring the protection of participants’ rights, safety, and well-being.
   • Responsibilities: Review and approve the trial protocol, informed consent forms, and ongoing conduct of the trial. IRBs ensure ethical standards are met.
5. Regulatory Authorities:
   • Role: Government agencies overseeing and regulating clinical trials to ensure public health and safety.
   • Responsibilities: Review and approve trial protocols, monitor trial conduct, and may grant marketing approval for new treatments. Examples nclude the U.S. FDA, European Medicines Agency (EMA), Turkish Medicines and Medical Devices Agency (TMMDA) and others.
6. Clinical Trial Coordinators/Managers:
   • Role: Professionals managing the day-to-day operations of the clinical trial.
   • Responsibilities: Coordinate participant recruitment, ensure adherence to the protocol, oversee data collection, and facilitate communication among different stakeholders.
7. Data and Safety Monitoring Boards (DSMBs):
   • Role: Independent groups monitoring the safety and efficacy of the trial.
   • Responsibilities: Review interim data, assess safety concerns, and make recommendations regarding the continuation, modification, or termination of the trial to ensure participant safety.
8. Contract Research Organizations (CROs):
   • Role: External companies hired to provide specific services for the clinical trial.
   • Responsibilities: Conduct monitoring, data management, statistical analysis, and other tasks as contracted by the sponsor, easing the burden on trial organizers.
9. Healthcare Providers:
   • Role: Physicians, nurses, and healthcare professionals directly involved in participant care.
   • Responsibilities: Administer treatments, monitor participants’ health, collect data, and report any adverse events or changes in health status.
10. Government Agencies:
    • Role: Government health departments overseeing clinical trials, often working in conjunction with regulatory authorities.
    • Responsibilities: May provide funding, coordinate research efforts, ensure compliance with national health policies, and support public health initiatives.
11. Pharmaceutical and Biotechnology Companies:
    • Role: Organizations developing and often sponsoring clinical trials, especially for new drugs or therapies.
    • Responsibilities: Initiate trials, provide funding, collaborate with investigators, and work towards bringing new treatments to market.
12. Community Advocates/Patient Advocacy Groups:
    • Role: Individuals or organizations representing the interests of patients.
    • Responsibilities: Provide input on study design from a patient perspective, advocate for participant rights, assist with recruitment, and contribute to community outreach to improve awareness and understanding.

The successful collaboration of these stakeholders is crucial for the ethical conduct, scientific validity, and overall success of clinical trials. Each group contributes to participant safety, data integrity, and the advancement of medical knowledge.

The key activities during a clinical trial at a clinical trial site, as per the clinical trial protocol, involve a detailed and systematic approach to ensure the study’s integrity, participant safety, and the generation of high-quality data. Here’s a comprehensive breakdown of these key activities:

1. Protocol Familiarization:
   • Principal Investigator (PI) and research staff thoroughly review the clinical trial protocol.
   • Gain a clear understanding of the study objectives, design, and procedures.
2. Site Selection and Initiation:
   • Select appropriate clinical trial sites based on the protocol’s requirements.
   • Initiate the site by conducting a site initiation visit, which includes training on the protocol, regulatory requirements, and Good Clinical Practice (GCP) guidelines.
3. Regulatory Compliance:
   • Obtain regulatory approvals from relevant health authorities and ethics committees.
   • Ensure ongoing compliance with regulatory requirements throughout the trial.
4. Informed Consent Process:
   • Administer the informed consent process to potential participants.
   • Ensure participants understand the study’s purpose, procedures, risks, and benefits before obtaining written consent.
5. Site Infrastructure Setup:
   • Establish necessary infrastructure and facilities for conducting the trial.
   • Ensure availability of adequate resources, including trained personnel, equipment, and supplies.
6. Staff Training:
   • Train site staff on protocol-specific procedures, GCP guidelines, and any specialized techniques required.
   • Ensure ongoing training and competency assessments.
7. Patient Recruitment and Screening:
   • Develop and implement a recruitment plan.
   • Screen and enroll eligible participants based on inclusion and exclusion criteria defined in the protocol.
8. Randomization and Blinding:
   • Implement randomization procedures as specified in the protocol.
   • Maintain blinding, if applicable, and ensure proper documentation.
9. Study Visits and Assessments:
   • Conduct scheduled study visits according to the protocol.
   • Perform required assessments, collect data, and record information accurately.
10. Safety Monitoring and Reporting:
    • Monitor participant safety throughout the trial.
    • Report adverse events (AEs) and serious adverse events (SAEs) promptly to the sponsor and relevant authorities.
11. Data Collection and Management:
    • Collect data as per the protocol using case report forms (CRFs) and other designated tools.
    • Ensure accurate and timely data entry into the electronic data capture (EDC) system.
12. Quality Control and Assurance:
    • Implement quality control measures to maintain data integrity.
    • Conduct regular internal audits to ensure compliance with GCP and protocol requirements.
13. Drug/Device Management:
    • Receive, store, dispense, and account for investigational products.
    • Monitor drug/device storage conditions and adherence to the protocol.
14. Protocol Amendments:
    • Implement any approved protocol amendments.
    • Communicate changes to the study team and ensure appropriate training.
15. Monitoring and Auditing:
    • Host monitoring visits by sponsor representatives or clinical research associates (CRAs).
    • Prepare for and participate in audits and inspections as needed.
16. Site Close-Out:
    • Complete all required documentation and data collection.
    • Conduct a close-out visit with the sponsor or monitor.
17. Data Analysis and Reporting:
    • Collaborate with the sponsor for data analysis.
    • Prepare and submit study reports and other required documents.
18. Archiving:
    • Archive all essential documents in accordance with regulatory requirements.
    • Maintain records for the required retention period.
19. Communication and Collaboration:
    • Maintain open communication with the sponsor, regulatory authorities, and other stakeholders.
    • Collaborate with other sites, if applicable, in multi-center trials.
20. Adherence to Ethical Considerations:
    • Uphold ethical standards in participant recruitment, treatment, and data collection.
    • Promptly report any ethical concerns to the IRB/ethics committee and the sponsor.
21. Continuous Improvement:
    • Regularly evaluate and improve site processes.
    • Address any issues or challenges promptly to enhance the overall conduct of the trial.
22. Documentation and Record-Keeping:
    • Maintain thorough and accurate documentation of all trial-related activities.
    • Keep complete and organized records for audit readiness.

These key activities collectively contribute to the successful execution of a clinical trial at a site, ensuring that the study is conducted in accordance with the protocol, regulatory requirements, and ethical standards. It’s essential for the site team to remain vigilant, well-trained, and collaborative throughout the trial duration.

After a clinical trial is completed, there are several key activities that need to be carried out to ensure proper closure, data analysis, and dissemination of results. Here is a detailed overview of the key activities post-clinical trial:

When the Clinical Trial is Fully Completed:

1. Data Lock and Database Closure:
   • Initiate data lock to prevent further modifications to the trial database.
   • Close the database to ensure the integrity of the collected data during subsequent analyses.
2. Data Cleaning and Quality Control:
   • Conduct thorough data cleaning to address discrepancies, errors, and missing data.
   • Implement quality control measures to validate the accuracy and completeness of the dataset.
3. Statistical Analysis:
   • Engage statisticians to perform comprehensive statistical analyses on the collected data.
   • Generate summary statistics, efficacy, and safety analyses to understand the trial outcomes.
4. Clinical Study Report (CSR) Preparation:
   • Form a writing team to prepare the CSR, covering aspects such as trial design, methodology, results, and conclusions.
   • Adhere to international guidelines (e.g., ICH E3) for CSR preparation.

After the Clinical Trial is Fully Completed:

5. Regulatory Submissions:
   • Submit the finalized CSR to regulatory authorities for approval.
   • Address any queries or requests for additional information from regulatory agencies.
6. Publication Planning:
   • Develop a comprehensive publication strategy for disseminating trial results through peer-reviewed journals.
   • Collaborate with authors to draft manuscripts and submit them to relevant scientific publications.
7. gov Update:
   • Update the ClinicalTrials.gov registry with the final trial results and any other required information.
8. Patient and Public Communication:
   • Communicate trial results to study participants in a clear and understandable manner.
   • Prepare materials for public communication, such as press releases or lay summaries.
9. Archiving and Documentation:
   • Archive all trial-related documents, including the final CSR, in accordance with regulatory standards.
   • Establish an organized system for documentation retrieval during inspections or audits.
10. Quality Assurance and Audits:
    • Conduct internal quality assurance checks to ensure adherence to protocols and regulatory requirements.
    • Prepare for and undergo external audits by regulatory authorities.
11. Long-Term Follow-up Planning:
    • If applicable, plan and initiate long-term follow-up studies to assess the intervention’s durability and safety.
12. Adverse Event Reporting:
    • Continue monitoring and reporting of adverse events that occur after the trial’s completion, if required.
13. Commercialization Planning (if applicable):
    • Develop plans for the commercialization of the intervention, including marketing, manufacturing, and distribution strategies.
14. Health Technology Assessment (HTA):
    • Collaborate with health authorities to conduct assessments, especially if seeking reimbursement for the intervention.
15. Data Sharing:
    • Consider sharing de-identified data with the scientific community to promote transparency and further research.
16. Budget Closeout:
    • Finalize the financial aspects of the trial, including closing budgets, settling invoices, and ensuring financial records are complete.
17. Staff Debriefing and Training:
    • Conduct debriefing sessions with the trial team to discuss lessons learned and areas for improvement.
    • Provide ongoing training for staff involved in the trial.
18. Follow-Up Studies and Post-Marketing Surveillance:
    • If applicable, plan and initiate any necessary follow-up studies or post-marketing surveillance.
19. Continued Regulatory Compliance:
    • Remain vigilant to ensure ongoing compliance with regulatory requirements even after the trial’s completion.

These activities collectively ensure a systematic and comprehensive conclusion to a clinical trial, emphasizing accurate reporting, transparency, and adherence to regulatory and ethical standards.

Finding clinical trials can be crucial for individuals seeking experimental treatments, investigators, and healthcare professionals. Here are some resources where you can find information about clinical trials worldwide and specifically in Turkiye:

Worldwide Clinical Trials:

1. ClinicalTrials.gov:
   • Website: ClinicalTrials.gov
   • Run by the U.S. National Library of Medicine, ClinicalTrials.gov is a comprehensive database of privately and publicly funded clinical studies conducted around the world.
2. EU Clinical Trials Register:
   • Website: EU Clinical Trials Register
   • This is the official European Union (EU) clinical trials register, providing information on interventional clinical trials conducted in the EU member states.
3. WHO International Clinical Trials Registry Platform (ICTRP):
   • Website: ICTRP
   • The ICTRP is a platform that aims to ensure that a complete view of research is accessible to all stakeholders and is a network of primary clinical trial registries from around the world.

Clinical Trials in Turkiye:

1. Türkiye Klinik Araştırmalar Portalı (Turkiye Clinical Trials Portal):
   • Website: Clinical Trials Portal
   • Managed by Turkish Medicines and Medical Devices Agency (TMMDA), this database provides information about ongoing and completed clinical trials in Turkiye.
2. CinicalTrials.gov (Turkiye-specific search):
   • You can use ClinicalTrials.gov and narrow down your search to Turkiye. Use the advanced search option and set the location to Turkiye to find relevant trials.
3. Local Hospitals and Research Institutions:
   • Check with local hospitals, universities, and research institutions in Turkiye. They often conduct clinical trials, and the information may be available on their websites or through direct inquiry.

Always consult with healthcare professionals and investigators to ensure the credibility and relevance of the clinical trials you are interested in. Keep in mind that participation in clinical trials should be discussed with your healthcare provider to make informed decisions about potential risks and benefits.